AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2840172
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate 20 mg/kg body weight/day for 20 days
Trial: 2840172
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate 20 mg/kg body weight/day for 40 days
Trial: 2840172
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate 20 mg/kg for 40 days
Trial: 2840172
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate 20 mg/kg for 20 days
Trial: 2840172
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate 15 mg/kg for 40 days
Trial: 2840172
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate 15 mg/kg for 20 days
Trial: 2840172
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate 10 mg/kg for 40 days
Trial: 2840172
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate 10 mg/kg for 20 days
Trial: 28595147
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (random assignment to different antipsychotic treatment)
Trial: 21501692
Drug: CIC‐HFA 282
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIC‐HFA 282 μg
Trial: 21501692
Drug: CIC‐HFA 282
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIC‐HFA 282 μg and 148 μg
Trial: 18440674
Drug: Plasmid pTHr
RxNorm normalized name: plasmin
DrugBank: Fibrinolysin (DB05254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmid pTHr DNA vaccine
Trial: 18440674
Drug: Modified vaccinia
RxNorm normalized name: Modified vaccinia ankara
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified vaccinia virus Ankara (MVA) vaccine
Trial: 16550943
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone for 2 weeks
Trial: 16550943
Drug: Intranasal budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal budesonide after oral prednisone
Trial: 16550943
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone and intranasal budesonide
Trial: 7519702
Drug: Buspirone 15
RxNorm normalized name: busPIRone 15 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 15 mg
Trial: 18362295
Drug: GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH therapy for 1 year
Trial: 16818280
Drug: Bortezomib 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.0 or 1.3 mg/m2 administered intravenously twice weekly for 2 weeks of a 3-week cycle for up to 8 cycles plus oral dexamethasone 20 mg on the day of and after each bortezomib dose
Trial: 14585874
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g human albumin
Trial: 1425271
Drug: Glucose only
RxNorm normalized name: Glucose only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose only (2 mg/kg.min)
Trial: 1425271
Drug: Glucose+xylitol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose+xylitol (1 mg/kg.min each)
Trial: 1425271
Drug: Glucose-containing electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-containing electrolyte solution (0.83 mg/kg.min glucose)
Trial: 6420383
Drug: Indomethacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (500 mg/3 days)
Trial: 29517675
Drug: Shenmai (SM)
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenmai (SM) injection
Trial: 29517675
Drug: 5% glucose
RxNorm normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% glucose (G)
Trial: 24759827
Drug: Early ART
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early ART (initiated 2 weeks after tuberculosis treatment onset)
Trial: 24759827
Drug: Late ART
RxNorm normalized name: Flavor PCCA Chocolate Artificial (Aldehyde Base)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late ART (initiated 8 weeks after tuberculosis treatment onset)
Trial: 21300002
Drug: Subarachnoid hemorrhage
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subarachnoid hemorrhage treatment (coiling, clipping)
Trial: 7790471
Drug: FAN bottles
RxNorm normalized name: danicopan
DrugBank: Danicopan (DB15401)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAN bottles (subset of patients on antimicrobial therapy)
Trial: 21327725
Drug: Rosuvastatin 40
RxNorm normalized name: rosuvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 40 mg (R group)
Trial: 21327725
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg plus fenofibrate 200 mg (RF group)
Trial: 21327725
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg plus n-3 fatty acids 2 g (RN group)
Trial: 16614537
Drug: Vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B6 1,200 mg/d
Trial: 16614537
Drug: Mianserin 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin 15 mg/d
Trial: 15610312
Drug: Intralesional steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional steroid injection (8 mg triamcinolone acetate into each quadrant)
Trial: 9164424
Drug: Fluvoxamine (50-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (50-150 mg/day, mean 102 +/- 44 mg/day)
Trial: 9164424
Drug: Paroxetine (20-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20-50 mg/day, mean 36 +/- 13 mg/day)
Trial: 2884494
Drug: Solid-phase radioimmunoassay
RxNorm normalized name: Corydalis solida whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solid-phase radioimmunoassay for antibodies against neutrophil cytoplasm
Trial: 27799299
Drug: Biobran (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biobran (1 g/day), n = 16
Trial: 22099384
Drug: Polydextrose (PDX;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polydextrose (PDX; 8 g/d)
Trial: 19035875
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg allopurinol for 8 weeks
Trial: 11565955
Drug: Loxoribine (doses:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxoribine (doses: 1 mg/kg, 5 mg/kg, 10 mg/kg)
Trial: 8246057
Drug: Normal glucose
RxNorm normalized name: Normal Glucose Control Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal glucose levels (<= 120 mg/dl)
Trial: 8246057
Drug: Hyperglycemia (>
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycemia (> 120 mg/dl)
Trial: 8246057
Drug: Normal mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal mean glucose levels (<= 120 mg/dl) between Days 3 and 7
Trial: 8246057
Drug: Elevated mean
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated mean glucose levels (> 120 mg/dl) between Days 3 and 7
Trial: 2937659
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment in addition to normal IVF procedures (group A)
Trial: 20479335
Drug: ISMN (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISMN (10 mg)
Trial: 20479335
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sildenafil (50 mg) and ISMN (10 mg)
Trial: 18493713
Drug: Levetiracetam (started
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (started at 250 mg qhs, increased to 1,500 mg bid as tolerated)
Trial: 18493713
Drug: Levetiracetam (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (treatment phase lasted 4 months)
Trial: 18493713
Drug: Levetiracetam (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (treatment for PMDD)
Trial: 15780443
Drug: 7-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-valent pneumococcal conjugate vaccine (PCV) given once or twice
Trial: 10627637
Drug: Intensified stem
RxNorm normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified stem cell transplant regimen (HDCT with escalated melphalan 160 mg/m2, fractionated total body irradiation 12 Gy, and infusional etoposide 60 mg/kg)
Trial: 1851649
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UH) 5000 units b.d.
Trial: 1851649
Drug: Logiparin 2500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Logiparin 2500 units daily
Trial: 1851649
Drug: Logiparin 3500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Logiparin 3500 units daily
Trial: 6815282
Drug: Doxycycline 200
RxNorm normalized name: doxycycline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 200 mg weekly for six weeks
Trial: 6815282
Drug: Doxycycline (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (single dose on day 3 of illness)
Trial: 27596360
Drug: Serelaxin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serelaxin (75 μg/kg/day)
Trial: 24401729
Drug: Internet-linked tablet
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-linked tablet computer-based intervention (the EDGE platform)
Trial: 19444413
Drug: No propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No propofol therapy
Trial: 18997670
Drug: Diane(35) Diario
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diane(35) Diario (35 microg ethinyl-estradiol plus 2 mg cyproterone acetate)
Trial: 15350250
Drug: Dalteparin 2500
RxNorm normalized name: dalteparin 2500 intl units/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin 2500 U, 2500 U, 5000 U, and 7500 U daily
Trial: 7521490
Drug: Intravenous diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diazepam (0.1 mg/kg in 20 min)
Trial: 2589674
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of agitated saline via a peripheral vein
Trial: 2589674
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of air via the epidural catheter
Trial: 2589674
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection (nothing injected)
Trial: 2589674
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of air via catheters accidentally inserted in epidural veins
Trial: 790358
Drug: Gefarnate, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefarnate, 50 mg four times daily
Trial: 790358
Drug: Placebo (dummy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (dummy capsules)
Trial: 25307511
Drug: Paricalcitol therapy
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paricalcitol therapy
Trial: 11641676
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (50 microg) every 3 hours
Trial: 9408917
Drug: Olanzapine 5
RxNorm normalized name: olanzapine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 5 +/‐ 2.5 mg/day
Trial: 9408917
Drug: Olanzapine 10
RxNorm normalized name: olanzapine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 10 +/‐ 2.5 mg/day
Trial: 9408917
Drug: Olanzapine 15
RxNorm normalized name: olanzapine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 15 +/‐ 2.5 mg/day
Trial: 9408917
Drug: Haloperidol 15
RxNorm normalized name: haloperidol 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 15 +/‐ 5 mg/day
Trial: 26141466
Drug: Daikenchuto (DKT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daikenchuto (DKT) 15.0 g/d
Trial: 19317163
Drug: Xiaoyu Zhixue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiaoyu Zhixue Tablet (XYZXT)
Trial: 19317163
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (adrenosin, vitamins C, K and P)
Trial: 442223
Drug: Cyclophosphamide +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide + Methotrexate + Fluorouracil (CMF) chemotherapy
Trial: 29893462
Drug: SOF/VEL/VOX (400/100/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOF/VEL/VOX (400/100/100 mg) daily for 12 weeks
Trial: 28374512
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol (SAL) via two different dry powder inhalers
Trial: 28374512
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol (SAL)
Trial: 9761804
Drug: Nebulized ipratropium
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized ipratropium bromide (500 microg, 2.5 ml) with albuterol
Trial: 19380203
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac (TDiclo)
Trial: 19380203
Drug: Oral diclofenac
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diclofenac (ODiclo)
Trial: 19380203
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac (TDiclo) + Oral diclofenac (ODiclo)
Trial: 15286220
Drug: Isotonic amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic amino acid (IAA) solution
Trial: 15286220
Drug: 0.25 normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 normal saline (NS) solution
Trial: 8237799
Drug: Intravenous 7E3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 7E3 (0.1 mg/kg [n = 5], 0.2 mg/kg [n = 22], 0.15 mg/kg [n = 13], 0.25 mg/kg [n = 20])
Trial: 8237799
Drug: Chimeric 7E3
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chimeric 7E3 bolus (up to 0.25 mg/kg) with intravenous continuous infusion of 7E3 (10 micrograms/min for 6 to 24 hours)
Trial: 8237799
Drug: Chimeric 7E3
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chimeric 7E3 bolus (up to 0.25 mg/kg) without intravenous continuous infusion of 7E3
Trial: 3684122
Drug: Bromocriptine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (50 mg intramuscular injection)
Trial: 3684122
Drug: Estandron prolongatum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estandron prolongatum (estradiol/testosterone ester combination, single intramuscular dose)
Trial: 28688001
Drug: Glecaprevir 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir 400 mg + Pibrentasvir 120 mg
Trial: 28688001
Drug: Glecaprevir 700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir 700 mg + Pibrentasvir 160 mg
Trial: 28688001
Drug: Glecaprevir (100-1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir (100-1200 mg) + Pibrentasvir (40-200 mg)
Trial: 28688001
Drug: Glecaprevir (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir (700 and 1200 mg)
Trial: 28688001
Drug: Glecaprevir up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir up to 400 mg + Pibrentasvir
Trial: 27149646
Drug: Prediagnostic aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prediagnostic aspirin use (1274 women)
Trial: 27149646
Drug: Prediagnostic aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prediagnostic aspirin use among lymph node-negative tumors
Trial: 27149646
Drug: Prediagnostic aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prediagnostic aspirin use among lymph node-positive tumors
Trial: 22315329
Drug: Rocuronium-sugammadex (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium-sugammadex (1 mg kg(‐1) rocuronium and 16 mg kg(‐1) sugammadex)
Trial: 22315329
Drug: Succinylcholine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine (1 mg kg(‐1))
Trial: 12637609
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa plus low-dose cytarabine
Trial: 10700786
Drug: Oral tenoxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tenoxicam (40 mg before surgery, 20 mg orally for 8 days)
Trial: 10700786
Drug: Intravenous tenoxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tenoxicam (40 mg after surgery, 40 mg i.v. at 24 h after surgery)
Trial: 7082779
Drug: Hydrochlorothiazide (HCT)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCT) 50 mg administered concurrently with propranolol
Trial: 7082779
Drug: INDERIDE (40/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INDERIDE (40/25 mg)
Trial: 7082779
Drug: INDERIDE (80/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INDERIDE (80/25 mg)
Trial: 7082779
Drug: Reference formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulations (separate tablets of INDERAL plus HYDRODIURIL)
Trial: 31788697
Drug: Aqueous iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aqueous iodine solution (AIS)
Trial: 18948412
Drug: CS-0777 (sphingosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-0777 (sphingosine 1-phosphate receptor-1 modulator)
Trial: 15561647
Drug: Gabapentin <1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin <1800 mg/d
Trial: 15561647
Drug: Gabapentin >=1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin >=1800 mg/d
Trial: 25678217
Drug: Ketotifen drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen drops (1 drop every 12 hours) with placebo pills (2 pills daily)
Trial: 25678217
Drug: Placebo eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo eye drops with ketotifen pills (2 pills daily)
Trial: 23812961
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of atomoxetine hydrochloride capsules (40 mg)
Trial: 23812961
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of atomoxetine hydrochloride capsules (40 mg)
Trial: 21861888
Drug: Capecitabine plus
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine plus bevacizumab (Cape-Bev) - capecitabine 1250 mg/m² bid for 14 days plus bevacizumab 7.5 mg/kg q3w
Trial: 21861888
Drug: Capecitabine plus
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) - capecitabine 800 mg/m² bid for 14 days, irinotecan 200 mg/m² on day 1, and bevacizumab 7.5 mg/kg q3w
Trial: 17920092
Drug: Argemone mexicana
RxNorm normalized name: ARGEMONE MEXICANA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argemone mexicana decoction, Group A: once daily for 3 days, n=23
Trial: 17920092
Drug: Argemone mexicana
RxNorm normalized name: ARGEMONE MEXICANA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argemone mexicana decoction, Group B: twice daily for 7 days, n=40
Trial: 17920092
Drug: Argemone mexicana
RxNorm normalized name: ARGEMONE MEXICANA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argemone mexicana decoction, Group C: four times daily for the first 4 days followed by twice daily for 3 days, n=17
Trial: 8624291
Drug: Cisplatin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (50 mg/m2, repeated courses every 28 days for 6 cycles)
Trial: 1096922
Drug: Experimental drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental drugs (various local anaesthetic agents)